Clinical trials: Amnestic Disorder
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia…
- Trial name
- NCT02972658
- Testing
- Lanabecestat
- Where
- 133 sites in United States, Australia and 12 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Mild Cognitive Impairment
Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment
Patients with mild cognitive impairment (MCI) are a group recognized at being at high risk of progressing to Alzheimer disease. Treatment of MCI with immunotherapy with intravenous immunoglobulins (IVIG) could potentially reduce…
- Trial name
- MCI (NCT01300728)
- Testing
- NewGam 10% IVIG
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Sutter Health
Long-Term Memory Decline, Mild Cognitive Impairment
Wayfinding Intervention in High-Fidelity Long-Term Memory
Therapeutic treatment is yet available for declining memory, which is an impairment affecting the quality of life for many older adults and patients with cognitive impairment.
- Trial name
- LABYR (NCT04253587)
- Testing
- LabyrinthVR, Coherence, Tablet
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer's Disease
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in…
- Trial name
- NCT01082965
- Testing
- Donepezil
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer
Mild Cognitive Impairment, Alzheimer's Disease
Comparison of PET Amyloid Imaging in Japanese and Western Subjects
This was a Phase 2, multicenter study to assess the extent and patterns of [18F] flutemetamol uptake in the brains of 3 groups of Japanese subjects: healthy volunteers (HV), amnestic mild cognitive impairment (aMCI), and probable…
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Healthy
- Trial name
- NCT02813070
- Testing
- [18F] Flutemetamol
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Alzheimer Disease, Mild Cognitive Impairment
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Olfactory identification deficits occur in patients with Alzheimer's disease (AD), are associated with disease severity, predict conversion from mild cognitive impairment (MCI) to AD and are associated with healthy elderly…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT01951118
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- New York State Psychiatric Institute
Mild Cognitive Impairment, Amnestic Mild Cognitive Impairment - aMCI
Cognitive Outcomes of Brain Stimulation As a Later-in-Life Treatment
This is a pilot study being done to attempt to improve episodic memory problems in persons with mild cognitive impairment (MCI).
- Trial name
- COBALT (NCT05564715)
- Testing
- NeuroElectric StarStim
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- NCT02910739
- Testing
- MK-8931
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment
The Advance Care Planning Group Visit intervention is a new intervention that uses the strengths of group visits to promote advance care planning conversations and documentation.
- Trial name
- ENACT-aMCI (NCT03711396)
- Testing
- Advance Care Planning Group Visits
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Mild Cognitive Impairment
Metformin in Amnestic Mild Cognitive Impairment
Hyperinsulinemia and type 2 diabetes (T2D) are important potential risk factors for cognitive decline and Alzheimer's disease (AD).
- Trial name
- MCI (NCT00620191)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
This 2-part, open-label study was designed to investigate the safety, tolerability, and efficacy of [18F]MK-6240, a Positron Emission Tomography (PET) imaging agent, for the quantification of neurofibrillary tangle (NFT)…
- Trial name
- NCT02562989
- Testing
- [18F]MK-6240, ~185 MBq, [18F]MK-6240, ~160 MBq
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
This study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI)…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- APECS (NCT01953601)
- Testing
- Verubecestat 12 mg (Parts 1 and 2), Verubecestat 40 mg (Parts 1 and 2)
- Volunteers
- 1,454 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
Efficacy and Safety Study of Shenwu Capsule
The purpose of this phase III study is to further evaluate the effects of shenwu capsule, a traditional Chinese herbal medicine, on cognition, function and memory in patients with amnestic mild cognitive impairment (MCI) who are…
- Trial name
- NCT01451749
- Testing
- Shenwu Capsule, Donepezil
- Where
- China
- Volunteers
- 324 people
- Sponsor
- North China Pharmaceutical Group Corporation
Obstructive Sleep Apnea, Mild Cognitive Impairment
Mild Cognitive Impairment and Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD.
- Trial name
- MEMORIES (NCT01482351)
- Testing
- CPAP adherence intervention, Attention control intervention
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- George Mason University
Amnestic Mild Cognitive Impairment, Traumatic Brain Injury
Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury
The study will examine the efficacy of high definition transcranial direct current stimulation (HD-tDCS) and its influence on episodic memory in patients with amnestic mild cognitive impairment and a history of Traumatic brain…
- Conditions
- Amnestic Mild Cognitive Impairment, Traumatic Brain Injury, Mild Traumatic Brain Injury
- Trial name
- NCT04504630
- Testing
- High Definition Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer Disease, Mild Memory Disturbance
The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study
The purpose of this research study is to learn whether it is possible and useful for caregivers to report behavioral or psychological symptoms of people with mild memory problems or Alzheimer's disease through a smartphone mobile…
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Trial name
- MOMENT (NCT04482036)
- Testing
- Mobile Phone Application Assessments, Standard Assessments
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indiana University
Mild Cognitive Impairment, Alzheimer's Disease
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically…
- Trial name
- NCT01028053
- Testing
- Flutemetamol (18F) Injection
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- GE Healthcare
Mild Cognitive Impairment
Interleaved TMS-fMRI for Hippocampal Stimulation: Modeling Dose-Response Relationship in Amnestic Mild Cognitive Impairment
Emerging evidence indicates that dysfunction of hippocampal synaptic plasticity, which precedes neuronal degeneration during the progression of Alzheimer's disease (AD), underlies the hallmark cognitive impairment.
- Trial name
- TMS-fMRI (NCT05515952)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Arizona